Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
STRONG BUY! Kurs eskaliert - A Star is Born!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DL44 | ISIN: SE0017885379 | Ticker-Symbol: 1CLA
München
21.01.25
20:17 Uhr
0,014 Euro
+0,001
+5,15 %
1-Jahres-Chart
CELL IMPACT AB Chart 1 Jahr
5-Tage-Chart
CELL IMPACT AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,0070,01821.01.
PR Newswire
915 Leser
Artikel bewerten:
(2)

Cell Impact AB: Cell Impact Signs Main Agreement with F.C.C.

Finanznachrichten News

KARLSKOGA, Sweden, May 7, 2024 /PRNewswire/ -- Today, Cell Impact has entered into a main agreement with Japanese company F.C.C., which governs the continued collaboration between the two companies to secure business primarily in Japan, India, and China.

Cell Impact has entered into a main agreement with Japanese company F.C.C., an agreement that governs the continued collaboration between the two companies to secure business primarily in Japan, India, and China. Based on Cell Impact Forming, a unique and patented technology for shaping flow plates, the companies can address customers' needs regarding design of flow plates and optimization of the production processes.

The main agreement leverages the strengths of both Cell Impact and F.C.C., outlining their respective responsibilities in various phases of upcoming deals.

"Leveraging our expertise and Cell Impact Forming, our unique and patented technology for shaping flow plates, we take responsibility for the initial cooperation with the customer, design and optimization of the product and process in future deals. This means assisting the customer in optimizing pattern design and developing tools and fixtures for analysis and verification, tailored for production," says Daniel Vallin, interim CEO of Cell Impact.

F.C.C. is a globally established supplier to the automotive industry. Some of the company's strengths are its size, infrastructure, and long-established networks within Automotive.

"We are pleased to collaborate with a successful manufacturer that has such a well-established network of contacts, especially in Japan, India, and China, where there is demand for flow plates initially for fuel cells. The agreement strengthens our position vis-à-vis world-leading players in the automotive industry," says Daniel Vallin.

The collaboration between F.C.C. and Cell Impact has evolved gradually since August 2022 when the companies jointly decided to install a demonstration line on-site in Hamamatsu, Japan. The purpose was to demonstrate the efficiency of Cell Impact's patented forming technology for potential customers in Japan and other parts of Asia.

Earlier today, Cell Impact announced a leasing agreement that will allow the company, together with F.C.C., to continue demonstrating Cell Impact Forming to customers and other stakeholders in the automotive industry.

For more information, please contact:
Daniel Vallin
CEO and IR contact, Cell Impact AB (publ)
+46730686620 or daniel.vallin@cellimpact.com

About Cell Impact

Cell Impact AB (publ) is a global supplier of advanced flow plates to fuel cell and electrolyzer manufacturers. The company has developed and patented a unique method for high velocity forming, Cell Impact Forming which is significantly more scalable and cost-efficient compared to conventional forming methods. Cell Impact Forming is an environmentally friendly forming technology that consumes no water and very little electrical power.

The Cell Impact share is listed on Nasdaq First North Growth Market and FNCA Sweden AB is the company's Certified Advisor (CA).

Photo - https://mma.prnewswire.com/media/2405641/Cell_Impact_AB.jpg
Logo - https://mma.prnewswire.com/media/1888196/4689602/Cell_Impact_AB_Logo.jpg

Cell Impact AB Logo

Cision View original content:https://www.prnewswire.co.uk/news-releases/cell-impact-signs-main-agreement-with-fcc-302137073.html

© 2024 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.